Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer : A pooled analysis of individual patient data from three randomized trials
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Cancer communications (London, England) - 44(2024), 2 vom: 04. Feb., Seite 278-281 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Tiantian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
52CMI0WC3Y |
|---|
| Anmerkungen: |
Date Completed 21.02.2024 Date Revised 05.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cac2.12512 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366366335 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366366335 | ||
| 003 | DE-627 | ||
| 005 | 20240405233323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cac2.12512 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM366366335 | ||
| 035 | |a (NLM)38145967 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Tiantian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer |b A pooled analysis of individual patient data from three randomized trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a atezolizumab |2 NLM | |
| 650 | 7 | |a 52CMI0WC3Y |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Zhou, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zezhou |e verfasserin |4 aut | |
| 700 | 1 | |a Bourbonne, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Käsmann, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Sundahl, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Jing-Ching Wu, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Jianjiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Zhengfei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer communications (London, England) |d 2018 |g 44(2024), 2 vom: 04. Feb., Seite 278-281 |w (DE-627)NLM28410809X |x 2523-3548 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:04 |g month:02 |g pages:278-281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cac2.12512 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 04 |c 02 |h 278-281 | ||